Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6255794 | 0.77 | KEAP1 (0.41) | KEAP1NFE2L2 | |
| SCHEMBL1547705 | 0.74 | — | — | |
| SCHEMBL1876976 | 0.74 | EPHX1 (0.39) | KEAP1NFE2L2 | |
| SCHEMBL28727636 | 0.73 | EPHX1 (0.38) | KEAP1NFE2L2 | |
| SCHEMBL9827947 | 0.71 | — | — | |
| SCHEMBL294826 | 0.71 | SMN1; SMN2 (0.32) | — | |
| SCHEMBL18884798 | 0.69 | CES2 (0.38) | KEAP1NFE2L2 | |
| SCHEMBL16592120 | 0.68 | TSHR (0.42) | KEAP1NFE2L2 | |
| SCHEMBL15507343 | 0.68 | KEAP1 (0.39) | KEAP1NFE2L2 | |
| SCHEMBL4728809 | 0.68 | KEAP1 (0.41) | KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036469-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTED AMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2009-02-05 | — | — | US | claimed |
| US-20090036469-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTED AMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036469-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTED AMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | PTGDR2, PTGDR, PTGER2 | KEAP1 2006/4885NFE2L2 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.